Cite
HARVARD Citation
Buckley, C. et al. (2020). Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study. Lancet. pp. e677-e688. [Online].